Divi's Laboratories Limited

BSE: 532488 NSE: DIVISLAB
Divi's Laboratories Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials and compliance.
CIN L24110TG1990PLC011854 Incorporated 12 October 1990 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: DIVISLAB · BSE: 532488 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹10,560 Cr
▲ 12.82% YoY
EBITDA · FY 2026
₹3,948 Cr
▲ 18.92% YoY
Net profit · FY 2026
₹2,568 Cr
▲ 17.21% YoY
Authorised capital
₹60 Cr
Registered with MCA
Paid-up capital
₹53.09 Cr
Issued & subscribed
Open charges
₹515 Cr
Satisfied ₹1,186.72 Cr
Company age
36 yrs
Est. 1990
Employees · EPFO
11,560
Latest available

About Divi's Laboratories Limited

Data last updated: 17 February 2026

Divi's Laboratories Limited is a public limited company based in Hyderabad, Telangana, India. It specialises in api manufacturers, a part of the broader pharmaceuticals sector. Incorporated on 12 October 1990, the company has been in operation for over 36 years.

Registered with ROC Hyderabad under CIN L24110TG1990PLC011854. Listed on BSE: 532488 and NSE: DIVISLAB.

Capital: an authorised share capital of ₹60 Cr and a paid-up capital of ₹53.09 Cr. Formerly known as Divi'S Research Centre Private Limited and Divi'S Laboratories Private Limited. It is led by directors including Nimmagadda Venkata Ramana and Murali Krishna Prasad Divi.

Last AGM: 11 August 2025. Financial statements filed for year ended 31 March 2025. Office: 1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032.

As per the financials filed for FY 2025, the company reported a revenue of ₹9,712 Cr, a growth of 19% compared to the previous year.

The company has a workforce of approximately 11,560 employees as per the latest available data.

The company is associated with 2 brands - Divis Nutraceuticals, Divis Laboratories. As per MCA filings, the company has open charges of ₹515 Cr and satisfied charges of ₹1,186.72 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website divislabs.com.

Company Details of Divi's Laboratories Limited
CIN L24110TG1990PLC011854
Registration Number 011854
Incorporation Date 12 October 1990
ROC Hyderabad
Listing Status Listed (BSE: 532488, NSE: DIVISLAB)
Company Status Active
Date of Last AGM 11 August 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Murali Krishna Prasad Divi Managing Director Nimmagadda Venkata Ramana Whole-Time Director Motaparti Nilima Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    divislabs.com
  • Social Media
  • Registered Address
    1 – 72/23(P)/Divis/303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032
  • Industry
    Pharma, API Manufacturers
Company report
Divi's Laboratories Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Divi's Laboratories Limited report

Financials, compliance, directors, charges, ownership and filings for Divi's Laboratories Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Divi's Laboratories Limited

Divi's Laboratories Limited has undergone 2 name changes throughout its history. The company was previously known as Divi's Research Centre Private Limited, and Divi's Laboratories Private Limited. The current legal name is Divi'S Laboratories Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Divi's Laboratories Limited Current
Divi's Research Centre Private Limited Previous
Divi's Laboratories Private Limited Previous

CIN History of Divi's Laboratories Limited

Divi's Laboratories Limited has one previous CIN (Corporate Identification Number): L24110AP1990PLC011854. The current CIN is L24110TG1990PLC011854, which is the unique identifier assigned by the Registrar of Companies.

CIN Status
L24110TG1990PLC011854 Current
L24110AP1990PLC011854 Previous

Associated Brands with Divi's Laboratories Limited

Divi's Laboratories Limited operates two associated brands: Divis Nutraceuticals and Divis Laboratories. These brands represent Divi's Laboratories Limited's diversified market presence and brand portfolio.

Brand Description Website
Divis Nutraceuticals
Manufacture of carotenoid and vitamin ingredients for food, beverage, and nutrition industries. divisnutraceuticals.com
Divis Laboratories
Contract manufacturer of APIs, intermediates, and building blocks of peptides and nucleotides divislabs.com

Competitors & Alternatives of Divi's Laboratories Limited

Brands and companies operating in the same space as Divi's Laboratories Limited include Laurus Labs, Symbiotec, NGL Fine Chem and 5 more.

Competitor Description Location Founded
Laurus Labs Laurus Labs Pharmaceutical and biotechnology company Hyderabad, India, India 2005
Symbiotec Symbiotec Non-sterile steroid hormone-based APIs and intermediates are manufactured. Indore, India, India 2002
NGL Fine Chem NGL Fine Chem CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicals Mumbai, India, India 1981
Beijing Biostar Technologies Beijing Biostar Technologies APIs, intermediates, and biochemical reagents are developed and manufactured. Beijing, China, China 2002
Sterling Pharma Solutions Sterling Pharma Solutions Contract development, manufacturing, and analytical services for APIs are offered. Dudley, United Kingdom, United Kingdom 2016
Provepharm Life Solutions Provepharm Life Solutions APIs and drug products are developed and valorized in pharmaceuticals. Marseille, France, France 1998
Snapdragon Chemistry Snapdragon Chemistry Drug discovery and development service provider Cambridge, United States, United States 2014
SeQuent SeQuent APIs are developed and manufactured for therapeutic areas. Bengaluru, India, India 2002

Business Activity of Divi's Laboratories Limited

Divi's Laboratories Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Divi's Laboratories Limited

Divi's Laboratories Limited is audited by Price Waterhouse Chartered Accountants LLP (ICAI peer reviewed, certificate valid till 2026-11-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
Price Waterhouse Chartered Accountants LLP (ICAI peer reviewed, certificate valid till 2026-11-30) FY 2026 Declaration of unmodified opinion

Board of Directors of Divi's Laboratories Limited

Divi's Laboratories Limited is currently managed by 12 directors, with 21 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Nimmagadda Venkata Ramana
Also directs: Maarrc Padmini Real Yield Llp
Whole-Time Director 01 Oct 1994 31 Years 9 Months Current
Murali Krishna Prasad Divi
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts And Agro Farms Private Limited
Managing Director 12 Oct 1990 35 Years 8 Months Current
Ganapaty Seru Director 22 Jul 2017 8 Years 11 Months Current
Sunaina Singh Director 28 Mar 2019 7 Years 3 Months Current
Rajendra Kumar Premchand
Also directs: Brs Medical Llp, Rksn Food & Beverages Private Limited, Indo-Asian Cardiac Research Centre Private Limited and 2 more
Director 25 May 2024 2 Years 1 Months Current
Motaparti Nilima
Also directs: Divi's Biotech Private Limited, Divi's Properties Private Limited, Divi's Resorts And Agro Farms Private Limited and 3 more
Whole-Time Director 27 Jun 2017 9 Years 0 Months Current
Showing 6 of 12 current directors. View all directors

Financials of Divi's Laboratories Limited FY 2026 filings available

Divi's Laboratories Limited reported revenue of ₹10,560 Cr (up 12.82% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹10,560 Cr ▲ 12.82%
Profit · FY 2026
₹2,568 Cr ▲ 17.21%
EBITDA · FY 2026
₹3,948 Cr ▲ 18.92%
Revenue₹ Cr · Consolidated05,00010,00015,000FY 2020: ₹5,394 Cr5,394FY 2020FY 2021: ₹6,969 Cr · +29.2% YoY6,969+29.2%FY 2021FY 2022: ₹8,960 Cr · +28.6% YoY8,960+28.6%FY 2022FY 2023: ₹7,768 Cr · -13.3% YoY7,768-13.3%FY 2023FY 2024: ₹7,845 Cr · +1% YoY7,845+1%FY 2024FY 2025: ₹9,360 Cr · +19.3% YoY9,360+19.3%FY 2025FY 2026: ₹10,560 Cr · +12.8% YoY10,560+12.8%FY 2026
Net Profit₹ Cr · Consolidated01,0002,0003,000FY 2020: ₹1,377 Cr1,377FY 2020FY 2021: ₹1,984 Cr · +44.2% YoY1,984+44.2%FY 2021FY 2022: ₹2,960 Cr · +49.2% YoY2,960+49.2%FY 2022FY 2023: ₹1,823 Cr · -38.4% YoY1,823-38.4%FY 2023FY 2024: ₹1,600 Cr · -12.3% YoY1,600-12.3%FY 2024FY 2025: ₹2,191 Cr · +36.9% YoY2,191+36.9%FY 2025FY 2026: ₹2,568 Cr · +17.2% YoY2,568+17.2%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year01,0002,0003,000Q1'25: ₹2,118 Cr · +19.1% YoY2,118+19.1%Q1'25Q2'25: ₹2,338 Cr · +22.5% YoY2,338+22.5%Q2'25Q3'25: ₹2,319 Cr · +25% YoY2,319+25%Q3'25Q4'25: ₹2,585 Cr · +12.2% YoY2,585+12.2%Q4'25Q1'26: ₹2,410 Cr · +13.8% YoY2,410+13.8%Q1'26Q2'26: ₹2,715 Cr · +16.1% YoY2,715+16.1%Q2'26Q3'26: ₹2,604 Cr · +12.3% YoY2,604+12.3%Q3'26Q4'26: ₹2,831 Cr · +9.5% YoY2,831+9.5%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹10,560 Cr ₹9,360 Cr ₹7,845 Cr ₹7,767.51 Cr ₹8,959.83 Cr ₹6,969.4 Cr ₹5,394.42 Cr
Other Income ₹507 Cr ₹352 Cr ₹339 Cr ₹344.66 Cr ₹113.87 Cr ₹62.56 Cr ₹189.63 Cr
Total Income ₹11,067 Cr ₹9,712 Cr ₹8,184 Cr ₹8,112.17 Cr ₹9,073.7 Cr ₹7,031.96 Cr ₹5,584.05 Cr
Cost of Materials Consumed ₹4,378 Cr ₹3,821 Cr ₹3,232 Cr ₹3,008.36 Cr ₹3,476.56 Cr ₹2,397.44 Cr ₹2,198.41 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹6 Cr ₹22.33 Cr ₹14.41 Cr ₹5.31 Cr ₹16.11 Cr
Changes in Inventories -₹285 Cr -₹96 Cr -₹109 Cr ₹23.03 Cr -₹523.83 Cr -₹78.67 Cr -₹105.98 Cr
Employee Benefit Expense ₹1,442 Cr ₹1,243 Cr ₹1,094 Cr ₹975.02 Cr ₹946.16 Cr ₹825.76 Cr ₹621.05 Cr
Finance Costs ₹23 Cr ₹2 Cr ₹3 Cr ₹67 Lakh ₹80 Lakh ₹87 Lakh ₹6.1 Cr
Depreciation & Amortisation ₹463 Cr ₹402 Cr ₹378 Cr ₹343.18 Cr ₹311.51 Cr ₹255.59 Cr ₹186.24 Cr
Other Expenses ₹1,584 Cr ₹1,424 Cr ₹1,417 Cr ₹1,370.95 Cr ₹1,164.59 Cr ₹959.62 Cr ₹842.66 Cr
Total Expenses ₹7,605 Cr ₹6,796 Cr ₹6,021 Cr ₹5,743.54 Cr ₹5,390.2 Cr ₹4,365.92 Cr ₹3,764.59 Cr
Profit Before Exceptional Items & Tax ₹3,462 Cr ₹2,916 Cr ₹2,163 Cr ₹2,368.63 Cr ₹3,683.5 Cr ₹2,666.04 Cr ₹1,819.46 Cr
Exceptional Items -₹74 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3,388 Cr ₹2,916 Cr ₹2,163 Cr ₹2,368.63 Cr ₹3,683.5 Cr ₹2,666.04 Cr ₹1,819.46 Cr
Total Tax Expense ₹820 Cr ₹725 Cr ₹563 Cr ₹545.25 Cr ₹723.05 Cr ₹681.75 Cr ₹442.92 Cr
Net Profit ₹2,568 Cr ₹2,191 Cr ₹1,600 Cr ₹1,823.38 Cr ₹2,960.45 Cr ₹1,984.29 Cr ₹1,376.54 Cr
  attributable to Owners ₹2,568 Cr ₹2,191 Cr ₹1,600 Cr ₹1,823.38 Cr ₹2,960.45 Cr ₹1,984.29 Cr -
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -
Other Comprehensive Income ₹21 Cr ₹3 Cr ₹0 ₹11.94 Cr ₹4.06 Cr ₹40 Lakh ₹35 Lakh
Total Comprehensive Income ₹2,589 Cr ₹2,194 Cr ₹1,600 Cr ₹1,835.32 Cr ₹2,964.51 Cr ₹1,984.69 Cr ₹1,376.89 Cr
EBITDA (computed) ₹3,948 Cr ₹3,320 Cr ₹2,544 Cr ₹2,712.48 Cr ₹3,995.81 Cr ₹2,922.5 Cr ₹2,011.8 Cr
Basic EPS ₹96.75 ₹82.53 ₹60.27 ₹68.69 ₹111.52 ₹74.75 ₹51.85
Diluted EPS ₹96.75 ₹82.53 ₹60.27 ₹68.69 ₹111.52 ₹74.75 ₹51.85
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹20,033 Cr ₹16,932 Cr ₹15,470 Cr ₹14,439 Cr
Non-current Assets ₹8,937 Cr ₹6,851 Cr ₹5,795 Cr ₹5,127.03 Cr
Current Assets ₹11,096 Cr ₹10,081 Cr ₹9,675 Cr ₹9,311.74 Cr
Property, Plant & Equipment ₹6,515 Cr ₹5,437 Cr ₹4,733 Cr ₹4,714.17 Cr
Inventories ₹3,954 Cr ₹3,236 Cr ₹3,184 Cr ₹3,000.41 Cr
Trade Receivables ₹2,984 Cr ₹2,731 Cr ₹2,156 Cr ₹1,792.53 Cr
Cash & Equivalents ₹128 Cr ₹415 Cr ₹363 Cr ₹169.7 Cr
Equity (Net Worth) ₹16,761 Cr ₹14,969 Cr ₹13,571 Cr ₹12,767 Cr
Equity Share Capital ₹53 Cr ₹53 Cr ₹53 Cr ₹53.09 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹2 Cr ₹0 ₹0
Total Debt (computed) ₹0 ₹2 Cr ₹0 ₹0
Current Liabilities ₹2,043 Cr ₹1,452 Cr ₹1,278 Cr ₹1,101.08 Cr
Total Liabilities ₹3,272 Cr ₹1,963 Cr ₹1,899 Cr ₹1,671.68 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹2,738 Cr ₹1,653 Cr ₹1,261 Cr ₹2,459.73 Cr ₹1,911.8 Cr
Investing Cash Flow -₹2,219 Cr -₹804 Cr -₹269 Cr -₹2,707.62 Cr -₹2,194.92 Cr
Financing Cash Flow -₹804 Cr -₹799 Cr -₹799 Cr -₹797.17 Cr -₹532.44 Cr
Capital Expenditure ₹2,520 Cr ₹1,438 Cr ₹1,003 Cr ₹473.02 Cr ₹713.2 Cr
Free Cash Flow (computed) ₹218 Cr ₹215 Cr ₹258 Cr ₹1,986.71 Cr ₹1,198.6 Cr
Dividends Paid ₹797 Cr ₹796 Cr ₹796 Cr ₹796.41 Cr ₹530.94 Cr
Net Change in Cash -₹285 Cr ₹50 Cr ₹193 Cr -₹1,045.06 Cr -₹815.56 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,831 Cr ₹2,604 Cr ₹2,715 Cr ₹2,410 Cr ₹2,585 Cr ₹2,319 Cr ₹2,338 Cr ₹2,118 Cr ₹2,303 Cr ₹1,855 Cr ₹1,909 Cr ₹1,778 Cr
Other Income ₹155 Cr ₹88 Cr ₹145 Cr ₹119 Cr ₹86 Cr ₹82 Cr ₹106 Cr ₹79 Cr ₹79 Cr ₹95 Cr ₹86 Cr ₹81 Cr
Total Income ₹2,986 Cr ₹2,692 Cr ₹2,860 Cr ₹2,529 Cr ₹2,671 Cr ₹2,401 Cr ₹2,444 Cr ₹2,197 Cr ₹2,382 Cr ₹1,950 Cr ₹1,995 Cr ₹1,859 Cr
Cost of Materials Consumed ₹1,214 Cr ₹1,217 Cr ₹937 Cr ₹1,010 Cr ₹931 Cr ₹1,021 Cr ₹976 Cr ₹893 Cr ₹898 Cr ₹794 Cr ₹711 Cr ₹829 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹6 Cr ₹0 ₹0 ₹0
Changes in Inventories -₹95 Cr -₹272 Cr ₹136 Cr -₹54 Cr ₹50 Cr -₹99 Cr -₹7 Cr -₹40 Cr -₹2 Cr -₹65 Cr ₹99 Cr -₹141 Cr
Employee Benefit Expense ₹381 Cr ₹367 Cr ₹354 Cr ₹340 Cr ₹350 Cr ₹297 Cr ₹304 Cr ₹292 Cr ₹297 Cr ₹268 Cr ₹266 Cr ₹263 Cr
Finance Costs ₹6 Cr ₹6 Cr ₹8 Cr ₹3 Cr ₹1 Cr ₹0 ₹1 Cr ₹0 ₹2 Cr ₹0 ₹1 Cr ₹0
Depreciation & Amortisation ₹120 Cr ₹118 Cr ₹113 Cr ₹112 Cr ₹107 Cr ₹99 Cr ₹99 Cr ₹97 Cr ₹95 Cr ₹95 Cr ₹95 Cr ₹93 Cr
Other Expenses ₹397 Cr ₹402 Cr ₹400 Cr ₹385 Cr ₹368 Cr ₹357 Cr ₹349 Cr ₹351 Cr ₹373 Cr ₹369 Cr ₹354 Cr ₹323 Cr
Total Expenses ₹2,023 Cr ₹1,838 Cr ₹1,948 Cr ₹1,796 Cr ₹1,807 Cr ₹1,675 Cr ₹1,722 Cr ₹1,593 Cr ₹1,669 Cr ₹1,461 Cr ₹1,526 Cr ₹1,367 Cr
Profit Before Exceptional Items & Tax ₹963 Cr ₹854 Cr ₹912 Cr ₹733 Cr ₹864 Cr ₹726 Cr ₹722 Cr ₹604 Cr ₹713 Cr ₹489 Cr ₹469 Cr ₹492 Cr
Exceptional Items ₹0 -₹74 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹963 Cr ₹780 Cr ₹912 Cr ₹733 Cr ₹864 Cr ₹726 Cr ₹722 Cr ₹604 Cr ₹713 Cr ₹489 Cr ₹469 Cr ₹492 Cr
Total Tax Expense ₹212 Cr ₹197 Cr ₹223 Cr ₹188 Cr ₹202 Cr ₹137 Cr ₹212 Cr ₹174 Cr ₹175 Cr ₹131 Cr ₹121 Cr ₹136 Cr
Net Profit ₹751 Cr ₹583 Cr ₹689 Cr ₹545 Cr ₹662 Cr ₹589 Cr ₹510 Cr ₹430 Cr ₹538 Cr ₹358 Cr ₹348 Cr ₹356 Cr
  attributable to Owners ₹751 Cr ₹583 Cr ₹689 Cr ₹545 Cr ₹662 Cr ₹589 Cr ₹510 Cr ₹430 Cr ₹538 Cr ₹358 Cr ₹348 Cr -
  attributable to NCI ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 -
Other Comprehensive Income -₹1 Cr ₹16 Cr ₹3 Cr ₹3 Cr ₹0 ₹1 Cr ₹1 Cr ₹1 Cr -₹7 Cr ₹5 Cr ₹1 Cr ₹1 Cr
Total Comprehensive Income ₹750 Cr ₹599 Cr ₹692 Cr ₹548 Cr ₹662 Cr ₹590 Cr ₹511 Cr ₹431 Cr ₹531 Cr ₹363 Cr ₹349 Cr ₹357 Cr
EBITDA (computed) ₹1,089 Cr ₹978 Cr ₹1,033 Cr ₹848 Cr ₹972 Cr ₹825 Cr ₹822 Cr ₹701 Cr ₹810 Cr ₹584 Cr ₹565 Cr ₹585 Cr
Basic EPS ₹28.31 ₹21.98 ₹25.97 ₹20.49 ₹24.93 ₹22.20 ₹19.20 ₹16.20 ₹20.25 ₹13.50 ₹13.11 ₹13.41
Diluted EPS ₹28.31 ₹21.98 ₹25.97 ₹20.49 ₹24.93 ₹22.20 ₹19.20 ₹16.20 ₹20.25 ₹13.50 ₹13.11 ₹13.41
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹10,388 Cr ₹9,198 Cr ₹7,665 Cr ₹7,625.3 Cr ₹8,879.82 Cr ₹6,798.61 Cr ₹5,310.57 Cr
Other Income ₹506 Cr ₹352 Cr ₹337 Cr ₹349.01 Cr ₹111.26 Cr ₹62.53 Cr ₹189.86 Cr
Total Income ₹10,894 Cr ₹9,550 Cr ₹8,002 Cr ₹7,974.31 Cr ₹8,991.08 Cr ₹6,861.14 Cr ₹5,500.43 Cr
Cost of Materials Consumed ₹4,260 Cr ₹3,760 Cr ₹3,210 Cr ₹2,979.49 Cr ₹3,439.79 Cr ₹2,365.5 Cr ₹2,182.66 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹244 Cr -₹83 Cr -₹127 Cr ₹50.16 Cr -₹449.99 Cr -₹100 Cr -₹94.1 Cr
Employee Benefit Expense ₹1,400 Cr ₹1,210 Cr ₹1,067 Cr ₹953.05 Cr ₹926.55 Cr ₹808.68 Cr ₹608.36 Cr
Finance Costs ₹23 Cr ₹1 Cr ₹3 Cr ₹52 Lakh ₹65 Lakh ₹69 Lakh ₹6.06 Cr
Depreciation & Amortisation ₹461 Cr ₹401 Cr ₹376 Cr ₹342.07 Cr ₹310.55 Cr ₹254.65 Cr ₹185.95 Cr
Other Expenses ₹1,484 Cr ₹1,332 Cr ₹1,341 Cr ₹1,294.92 Cr ₹1,087.01 Cr ₹903.75 Cr ₹798.21 Cr
Total Expenses ₹7,384 Cr ₹6,621 Cr ₹5,870 Cr ₹5,620.21 Cr ₹5,314.56 Cr ₹4,233.27 Cr ₹3,687.14 Cr
Profit Before Exceptional Items & Tax ₹3,510 Cr ₹2,929 Cr ₹2,132 Cr ₹2,354.1 Cr ₹3,676.52 Cr ₹2,627.87 Cr ₹1,813.29 Cr
Exceptional Items -₹74 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹3,436 Cr ₹2,929 Cr ₹2,132 Cr ₹2,354.1 Cr ₹3,676.52 Cr ₹2,627.87 Cr ₹1,813.29 Cr
Total Tax Expense ₹829 Cr ₹720 Cr ₹556 Cr ₹545.95 Cr ₹727.98 Cr ₹673.15 Cr ₹440.58 Cr
Net Profit ₹2,607 Cr ₹2,209 Cr ₹1,576 Cr ₹1,808.15 Cr ₹2,948.54 Cr ₹1,954.72 Cr ₹1,372.71 Cr
Other Comprehensive Income ₹6 Cr -₹2 Cr -₹1 Cr ₹2.33 Cr ₹2.18 Cr ₹16 Lakh -₹5.21 Cr
Total Comprehensive Income ₹2,613 Cr ₹2,207 Cr ₹1,575 Cr ₹1,810.48 Cr ₹2,950.72 Cr ₹1,954.88 Cr ₹1,367.5 Cr
EBITDA (computed) ₹3,994 Cr ₹3,331 Cr ₹2,511 Cr ₹2,696.69 Cr ₹3,987.72 Cr ₹2,883.21 Cr ₹2,005.3 Cr
Basic EPS ₹98.19 ₹83.20 ₹59.37 ₹68.11 ₹111.07 ₹73.63 ₹51.71
Diluted EPS ₹98.19 ₹83.20 ₹59.37 ₹68.11 ₹111.07 ₹73.63 ₹51.71
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹19,954 Cr ₹16,824 Cr ₹15,362 Cr ₹14,352 Cr
Non-current Assets ₹8,920 Cr ₹6,845 Cr ₹5,790 Cr ₹5,116.17 Cr
Current Assets ₹11,034 Cr ₹9,979 Cr ₹9,572 Cr ₹9,235.45 Cr
Property, Plant & Equipment ₹6,514 Cr ₹5,436 Cr ₹4,733 Cr ₹4,713.48 Cr
Inventories ₹3,711 Cr ₹3,033 Cr ₹2,985 Cr ₹2,780.45 Cr
Trade Receivables ₹3,228 Cr ₹2,855 Cr ₹2,273 Cr ₹1,964.3 Cr
Cash & Equivalents ₹85 Cr ₹396 Cr ₹344 Cr ₹144.17 Cr
Equity (Net Worth) ₹16,711 Cr ₹14,895 Cr ₹13,484 Cr ₹12,705 Cr
Equity Share Capital ₹53 Cr ₹53 Cr ₹53 Cr ₹53.09 Cr
Borrowings (Non-current) ₹0 ₹0 ₹0 ₹0
Borrowings (Current) ₹0 ₹2 Cr ₹0 ₹0
Total Debt (computed) ₹0 ₹2 Cr ₹0 ₹0
Current Liabilities ₹2,019 Cr ₹1,420 Cr ₹1,259 Cr ₹1,078.37 Cr
Total Liabilities ₹3,243 Cr ₹1,929 Cr ₹1,878 Cr ₹1,646.2 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹2,711 Cr ₹1,650 Cr ₹1,266 Cr ₹2,447.95 Cr ₹1,910.16 Cr
Investing Cash Flow -₹2,218 Cr -₹803 Cr -₹268 Cr -₹2,706.75 Cr -₹2,195.4 Cr
Financing Cash Flow -₹802 Cr -₹797 Cr -₹798 Cr -₹796.59 Cr -₹531.5 Cr
Capital Expenditure ₹2,519 Cr ₹1,437 Cr ₹1,002 Cr ₹472.15 Cr ₹713.68 Cr
Free Cash Flow (computed) ₹192 Cr ₹213 Cr ₹264 Cr ₹1,975.8 Cr ₹1,196.48 Cr
Dividends Paid ₹797 Cr ₹796 Cr ₹796 Cr ₹796.41 Cr ₹530.94 Cr
Net Change in Cash -₹309 Cr ₹50 Cr ₹200 Cr -₹1,055.39 Cr -₹816.74 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹2,793 Cr ₹2,578 Cr ₹2,660 Cr ₹2,357 Cr ₹2,536 Cr ₹2,297 Cr ₹2,302 Cr ₹2,063 Cr ₹2,259 Cr ₹1,808 Cr ₹1,868 Cr ₹1,730 Cr
Other Income ₹154 Cr ₹87 Cr ₹146 Cr ₹119 Cr ₹87 Cr ₹82 Cr ₹105 Cr ₹79 Cr ₹79 Cr ₹94 Cr ₹85 Cr ₹80 Cr
Total Income ₹2,947 Cr ₹2,665 Cr ₹2,806 Cr ₹2,476 Cr ₹2,623 Cr ₹2,379 Cr ₹2,407 Cr ₹2,142 Cr ₹2,338 Cr ₹1,902 Cr ₹1,953 Cr ₹1,810 Cr
Cost of Materials Consumed ₹1,173 Cr ₹1,191 Cr ₹907 Cr ₹989 Cr ₹910 Cr ₹1,015 Cr ₹953 Cr ₹882 Cr ₹910 Cr ₹771 Cr ₹706 Cr ₹823 Cr
Purchases of Stock-in-Trade ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Changes in Inventories -₹70 Cr -₹246 Cr ₹144 Cr -₹72 Cr ₹59 Cr -₹87 Cr ₹1 Cr -₹56 Cr -₹10 Cr -₹63 Cr ₹94 Cr -₹148 Cr
Employee Benefit Expense ₹370 Cr ₹356 Cr ₹344 Cr ₹330 Cr ₹341 Cr ₹288 Cr ₹296 Cr ₹285 Cr ₹290 Cr ₹261 Cr ₹260 Cr ₹256 Cr
Finance Costs ₹6 Cr ₹6 Cr ₹8 Cr ₹3 Cr ₹0 ₹0 ₹1 Cr ₹0 ₹2 Cr ₹0 ₹1 Cr ₹0
Depreciation & Amortisation ₹120 Cr ₹116 Cr ₹113 Cr ₹112 Cr ₹107 Cr ₹99 Cr ₹98 Cr ₹97 Cr ₹94 Cr ₹95 Cr ₹94 Cr ₹93 Cr
Other Expenses ₹377 Cr ₹370 Cr ₹370 Cr ₹367 Cr ₹345 Cr ₹334 Cr ₹323 Cr ₹331 Cr ₹352 Cr ₹348 Cr ₹334 Cr ₹308 Cr
Total Expenses ₹1,976 Cr ₹1,793 Cr ₹1,886 Cr ₹1,729 Cr ₹1,762 Cr ₹1,649 Cr ₹1,672 Cr ₹1,539 Cr ₹1,638 Cr ₹1,412 Cr ₹1,489 Cr ₹1,332 Cr
Profit Before Exceptional Items & Tax ₹971 Cr ₹872 Cr ₹920 Cr ₹747 Cr ₹861 Cr ₹730 Cr ₹735 Cr ₹603 Cr ₹700 Cr ₹490 Cr ₹464 Cr ₹478 Cr
Exceptional Items ₹0 -₹74 Cr ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0 ₹0
Profit Before Tax ₹971 Cr ₹798 Cr ₹920 Cr ₹747 Cr ₹861 Cr ₹730 Cr ₹735 Cr ₹603 Cr ₹700 Cr ₹490 Cr ₹464 Cr ₹478 Cr
Total Tax Expense ₹215 Cr ₹200 Cr ₹224 Cr ₹190 Cr ₹194 Cr ₹136 Cr ₹217 Cr ₹173 Cr ₹169 Cr ₹132 Cr ₹122 Cr ₹133 Cr
Net Profit ₹756 Cr ₹598 Cr ₹696 Cr ₹557 Cr ₹667 Cr ₹594 Cr ₹518 Cr ₹430 Cr ₹531 Cr ₹358 Cr ₹342 Cr ₹345 Cr
Other Comprehensive Income -₹6 Cr ₹13 Cr ₹0 -₹1 Cr -₹1 Cr ₹0 ₹0 -₹1 Cr -₹3 Cr ₹1 Cr ₹0 ₹1 Cr
Total Comprehensive Income ₹750 Cr ₹611 Cr ₹696 Cr ₹556 Cr ₹666 Cr ₹594 Cr ₹518 Cr ₹429 Cr ₹528 Cr ₹359 Cr ₹342 Cr ₹346 Cr
EBITDA (computed) ₹1,097 Cr ₹994 Cr ₹1,041 Cr ₹862 Cr ₹968 Cr ₹829 Cr ₹834 Cr ₹700 Cr ₹796 Cr ₹585 Cr ₹559 Cr ₹571 Cr
Basic EPS ₹28.44 ₹22.56 ₹26.24 ₹20.95 ₹25.12 ₹22.39 ₹19.51 ₹16.18 ₹19.99 ₹13.50 ₹12.89 ₹12.99
Diluted EPS ₹28.44 ₹22.56 ₹26.24 ₹20.95 ₹25.12 ₹22.39 ₹19.51 ₹16.18 ₹19.99 ₹13.50 ₹12.89 ₹12.99
Latest 12 quarters shown of 25 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Divi's Laboratories Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Divi's Laboratories Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 51.88%, foreign institutional investors hold 20.29%, domestic institutional investors hold 19.22%, retail and other public shareholders hold 8.60% of Divi's Laboratories Limited. The company had 228,006 shareholders on record.

Promoters: 51.88%DII (Domestic Institutional): 19.22%FII (Foreign Institutional): 20.29%Retail & Others: 8.60%
Mar 2026
QUARTER
51.88% Promoters
19.22% DII (Domestic Institutional)
20.29% FII (Foreign Institutional)
8.60% Retail & Others
Promoter holding - history
Now 51.88% · Mar 2026High 52.08% · Dec 2015Low 51.88% · Dec 2025
50%51%52%53%54%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 52.08%Mar 2016: 52.08%Jun 2016: 52.08%Sep 2016: 52.06%Dec 2016: 52.06%Mar 2017: 52.07%Jun 2017: 52.07%Sep 2017: 52.07%Dec 2017: 52.07%Mar 2018: 52.05%Jun 2018: 52.03%Sep 2018: 52.02%Dec 2018: 52.01%Mar 2019: 52.01%Jun 2019: 52.01%Sep 2019: 52.01%Dec 2019: 52.00%Mar 2020: 51.97%Jun 2020: 51.97%Sep 2020: 51.96%Dec 2020: 51.95%Mar 2021: 51.95%Jun 2021: 51.95%Sep 2021: 51.95%Dec 2021: 51.95%Mar 2022: 51.94%Jun 2022: 51.94%Sep 2022: 51.94%Dec 2022: 51.94%Mar 2023: 51.94%Jun 2023: 51.93%Sep 2023: 51.93%Dec 2023: 51.92%Mar 2024: 51.92%Jun 2024: 51.90%Sep 2024: 51.89%Dec 2024: 51.89%Mar 2025: 51.89%Jun 2025: 51.89%Sep 2025: 51.89%Dec 2025: 51.88%Mar 2026: 51.88%52.08%51.88%51.88%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters51.88%51.88%51.89%51.89%51.89%51.89%
Public48.12%48.12%48.11%48.11%48.11%48.11%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters51.88%51.89%51.92%51.94%51.94%51.95%51.97%52.01%52.05%52.07%52.08%
Public48.12%48.11%48.08%48.06%48.06%48.05%48.03%47.99%47.95%47.93%47.92%
Promoter change (YoY, %pts)-0.01-0.03-0.02+0.00-0.01-0.02-0.04-0.04-0.02-0.01-

Board & Governance of Divi's Laboratories Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Divi's Laboratories Limited has 10 directors - 5 independent and 5 executive. The board is chaired by RAMESHBABU VENKATA NIMMAGADDA.

DirectorPositionOn board sinceListed boards
RAMESHBABU VENKATA NIMMAGADDA Non-Executive - Independent Director · Chairperson 2017-06-27 1
MURALI KRISHNA PRASAD DIVI Executive Director · MD 1990-10-12 1
NIMMAGADDA VENKATA RAMANA Executive Director 1994-10-01 1
SATCHANDRA KIRAN DIVI Executive Director · CEO 2001-08-10 1
NILIMA PRASAD DIVI Executive Director 2017-06-27 1
DEVENDRA RAO SUREDDY Executive Director 2024-02-10 1
GANAPATY SERU Non-Executive - Independent Director 2017-07-22 1
SUNAINA SINGH Non-Executive - Independent Director 2019-03-28 1
VEERAYYA CHOWDARY KOSARAJU Non-Executive - Independent Director 2020-01-04 5
RAJENDRA KUMAR PREMCHAND Non-Executive - Independent Director 2024-05-25 1
Board Committees
CommitteeMembers
Audit Committee VEERAYYA CHOWDARY KOSARAJU (Chairperson), GANAPATY SERU, RAMESHBABU VENKATA NIMMAGADDA, RAJENDRA KUMAR PREMCHAND
Nomination and remuneration committee GANAPATY SERU (Chairperson), RAMESHBABU VENKATA NIMMAGADDA, SUNAINA SINGH, VEERAYYA CHOWDARY KOSARAJU
Stakeholders Relationship Committee RAMESHBABU VENKATA NIMMAGADDA (Chairperson), SUNAINA SINGH, DEVENDRA RAO SUREDDY
Risk Management Committee SATCHANDRA KIRAN DIVI (Chairperson), NILIMA PRASAD DIVI, DEVENDRA RAO SUREDDY, GANAPATY SERU, LINGAMNENI RAMESH BABU
Corporate Social Responsibility Committee RAMESHBABU VENKATA NIMMAGADDA (Chairperson), MURALI KRISHNA PRASAD DIVI, NILIMA PRASAD DIVI

Charges & Borrowings of Divi's Laboratories Limited

Open charges
₹515 Cr
Satisfied charges
₹1,186.72 Cr
Breakdown by lending institutions
State Bank of India₹454.50 Cr
State Bank of Hyderabad₹254.84 Cr
Others₹109.50 Cr
State Bank of Hyderabad (Sbh)₹97.74 Cr
Hdfc Bank Limited₹60.50 Cr
Others₹209.64 Cr
Latest charge details
DateLenderAmountStatus
27 Feb 2019 Hdfc Bank Limited ₹60.5 Cr Satisfied
28 Oct 2006 The Bank of Nova Scotia ₹20.9 Cr Satisfied
15 Jun 2006 State Bank of India - Overseas Branch ₹50.58 Cr Satisfied
28 Dec 2005 Bank of Nova Scotia ₹20 Cr Satisfied
06 Oct 2005 State of India ₹27.45 Cr Satisfied

Total charge records: 26 View all charges

Employees and EPFO Compliance at Divi's Laboratories Limited

Divi's Laboratories Limited has a workforce of 11,560 employees as of Sep 10, 2024.

Employee count
11,560
Active EPFO establishments
3
Employee growth
3.88%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Divi's Laboratories Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Divi's Laboratories Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Divi's Laboratories Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Divi's Laboratories Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Divi's Laboratories Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Divi's Laboratories Limited

MSME Payment Delays by Divi's Laboratories Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Divi's Laboratories Limited

Subsidiaries & Group Companies of Divi's Laboratories Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Divi's Laboratories Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Divi's Laboratories Limited

MCA Filings & Documents of Divi's Laboratories Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Divi's Laboratories Limited

Charges
07 Feb 2026
A charge registered on 27 Feb 2019 via Charge ID 100246839 with Hdfc Bank Limited was fully satisfied on 07 Feb 2026.
Charges
31 Jan 2026
A charge registered on 14 Dec 1995 via Charge ID 90137808 with State Bank Of India was fully satisfied on 31 Jan 2026.
Activity
11 Aug 2025
Divi'S Laboratories Limited last Annual general meeting of members was held on 11 Aug 2025 as per latest MCA records.
Directors
02 Aug 2025
Venkatesa Perumallu Pasumarthy was appointed as a Cfo on 02 Aug 2025 & has been associated with this company since 11 months 6 days.
Activity
31 Mar 2025
Divi'S Laboratories Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad.
Directors
25 May 2024
Rajendra Kumar Premchand was appointed as a Director on 25 May 2024 & has been associated with this company since 2 years 1 month.

Recent News on Divi's Laboratories Limited

Stocks in focus today: 21 April, 2025
21 Apr 2025 · Thehindubusinessline

Frequently Asked Questions about Divi's Laboratories Limited

Divi's Laboratories Limited is an active public limited company in the pharma sector based in Hyderabad, Telangana, India. It was incorporated on 12 October 1990 (36+ years old) and is registered under CIN L24110TG1990PLC011854. Listed on BSE: 532488 and NSE: DIVISLAB. The company has 11,560 employees.

Divi's Laboratories Limited reported revenue of ₹9,712 Cr for FY 2025 (up 19.00% YoY).

The current directors of Divi's Laboratories Limited are:

The primary industry of Divi's Laboratories Limited is pharma. The company specifically operates in api manufacturers. The company is currently active in this sector.

Yes. Divi's Laboratories Limited is listed on both BSE (code: 532488) and NSE (symbol: DIVISLAB).

Divi's Laboratories Limited can be reached at the registered office: 1 – 7223PDivis303 Divi Towers Cyber Hills Gachibowli, Hyderabad, Telangana, India – 500032, or through the website divislabs.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available